Medicines for Malaria Venture (MMV)

A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Where meds are made impacts who can access them.

Africa is heavily reliant on imports for the medicines needed to fight #malaria.

MMV works with African manufacturers & @AfricaCDC to strengthen local production & bring medicines closer to patients. https://t.co/uPv2Smn83g

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

What can investments in global health make possible?

Through @EDCTP, EU investments advance new health tools, build scientific capacity & attract additional funding, with every €1 mobilizing more than €1 from other sources.

Read our paper: https://t.co/h9Bs2DCQrX

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

When resources are under pressure, innovation becomes even more important.

Drug & insecticide resistance, climate change & conflict threaten #malaria progress.

New tools can keep us ahead of resistance, simplify care & make the most of limited resources https://t.co/wZ1bBQFGyV

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

There are places we expect #malaria transmission. Germany isn't one of them.

Cases have appeared near Frankfurt Airport. As temps rise, transmission conditions are changing.

A reminder that reducing malaria everywhere strengthens global health security. https://t.co/eAglwgRAZi

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

What keeps progress against #malaria moving?

In Liverpool, @malarianomoreuk ambassador @goodolgab1 put that question to malaria scientists & global health experts.

See what they had to say.

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Following encouraging Phase 2a results, MMV will lead the next phase of cabamiquine's development.

Long-acting cabamiquine, with potential to become a single-dose treatment or prevention option, could help address drug resistance & block transmission: https://t.co/NulRxO23tR

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

PNG shoulders a disproportionate share of the Indo-Pacific's #malaria burden.

Closing the gap means understanding why progress is harder in some settings vs others.

In PNG, MMV met with partners & communities to explore the strategies and tools needed to accelerate elimination.

[Asia Pacific Malaria Elimination Network @APMEN]

📢 APMEN TechTalks | Improving Access to G6PD Testing at the Community Level

Join the APMEN Vivax Working Group for a practical discussion on community-level G6PD screening and lessons from field implementation.

📅 29 Sep 2026
🕒 2 PM Singapore (GMT+8)

🔗 Register: https://t.co/3ZDV88qAXW

#APMEN #Malaria #G6PD #Vivax

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

The Malaria Science Index shows how investment in #malaria R&D strengthens global health security and delivers #innovation beyond malaria.

It also shows how UK science benefits from international collaboration.

Sustained investment is key to elimination: https://t.co/9XKZ4roAR6

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Each breakthrough in global health starts with a partnership.

The UK is committing more than £100m to product development partnerships (PDPs). For #malaria, sustained investment in PDPs like MMV can help make the next breakthroughs possible.

Read more: https://t.co/6IhHh3bwKl

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

One dose to cure #malaria.

That's the ambition behind WANECAM3, an Africa-Europe consortium developing new tools to change how we fight the disease.

Prof. Abdoulaye Djimdé & his team in Mali are providing the scientific leadership to help make it happen: https://t.co/F7mOWJw5e9

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

What will it take to end #malaria?

New tools that can simplify care. Single-dose cures and long-acting prevention could become elimination accelerators, taking us closer to the finish line.

Sustained investment can help get them there.

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

#ClimateChange is no longer simply a future threat, but a reality we need to manage and adapt to.

For #malaria, building resilience is critical. This means developing simpler medicines that are easier to deliver and use, while strengthening health systems and supply chains.

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

#Malaria treatment and prevention needs vary by patient, context and setting.

A new review explores how #innovation must respond, from simplifying treatment and providing longer-lasting protection to staying ahead of drug resistance.

Read more: https://t.co/Lp7VrnBZKw

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Different patients need medicines designed for their particular needs.

Coartem® Baby, the first antimalarial developed for newborns & young infants 2–5 kg, is now included in the WHO Guidelines for #malaria, supporting broader access.

Read more https://t.co/36SWGIX8S6

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Does your organization have insights into how AI can improve clinical trial design and documentation?

MMV, @DNDi and @gardp_amr are mapping AI solutions for clinical study design, operations and medical writing.

Submission deadline: 7 October
Learn more: https://t.co/AeBgiFM3hC

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

Women should be protected through research, not from it.

Healthcare decisions need evidence, but pregnant & breastfeeding women have historically been excluded from clinical research, leaving critical data gaps.

Read our recommendations for ICH E21: https://t.co/LmUMDDFQOr

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

#Malaria prevalence in Nigeria among children aged 6–59 months has declined by nearly 64% over the past 15 years.

Sustained investment in prevention tools like SMC, treatment, surveillance and public awareness has helped drive this progress.

Learn more: https://t.co/yTRwEcIPvh

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

MMV expresses profound sadness at the news of Vasee Moorthy’s untimely passing – we have lost an exceptional champion of global health.

We will miss him sorely and send our deepest condolences to his myriad friends and his beloved family.

[Medicines for Malaria Venture (MMV) @MedsforMalaria]

MMV has launched a request for information to identify  organizations based in or operating in malaria-endemic countries for a new request for information on #malaria market intelligence and evidence generation.

Deadline: 14 October

Learn more: https://t.co/Z0L9HrQNdU